Search results
Results From The WOW.Com Content Network
AstraZeneca plc ( / ˌæstrəˈzɛnəkə /) ( AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [ 2 ][ 3 ][ 4 ] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [ 5 ] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal ...
For the fiscal year 2018,Bristol Myers Squibb reported earnings of US$1.007 billion, with an annual revenue of US$20.776 billion, an increase of 6.9% over the previous fiscal cycle. Bristol-Myers Squibb's shares traded at over $55 per share, and its market capitalization was valued at over US$81.6 billion in October 2018. [ 90 ]
GW Pharmaceuticals Limited[ 1] is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country. [ 3] Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food ...
On Thursday, AstraZeneca Plc (NASDAQ:AZN) reported second-quarter sales of $12.94 billion, up 13% year over year (+17% at constant currency), beating the consensus of $12.75 billion. The company ...
List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...
Show comments. AstraZeneca aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday, boosted by the expected launch of 20 new medicines and through growth in its cancer ...
v. t. e. The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield[ 31 ] and Vaxzevria[ 1 ][ 32 ] among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, [ 33 ][ 34 ][ 35 ] using as a vector the modified ...
An AstraZeneca executive last week said the company expected a limited impact because its diabetes drug Farxiga will face competition from cheaper generic drugs around three months after the new ...